secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-10-19T12:00:28+00:00
Accession:  0001213900-26-110477
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CorMedix FDA accepts REZZAYO sNDA for fungal prophylaxis with Priority Review; PDUFA set for Q1 2027
--------------------------------------------------------------------------------

- FDA accepted for filing the sNDA, submitted by partner Mundipharma, for REZZAYO (rezafungin) prophylaxis of invasive fungal disease in adults undergoing allogeneic HSCT.
- Priority Review granted with a PDUFA target action date in Q1 2027; CorMedix targets beginning promotional efforts in H2 2027.
- sNDA supported by the Phase III ReSPECT pivotal study, for which CorMedix reported positive topline results in April 2026.
- Rezafungin holds U.S. orphan drug exclusivity through 2035 and patent coverage through 2038; REZZAYO is already approved for candidemia and invasive candidiasis.
- Company cautions acceptance and Priority Review do not assure approval; FDA could request more data, extend review, or grant narrower labeling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/0001213900-26-110477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea0308957-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-110477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer